Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.

Head and Neck Squamous Cell Carcinoma Clinical Trials

15 recruiting trials for Head and Neck Squamous Cell Carcinoma. Eligibility criteria explained in plain English.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
15
Total Trials
15
Recruiting Now
2
Phase 3 Trials
10
Sponsors

Recruiting Trials

RECRUITINGPhase 1NCT04119024

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic...

This phase I trial studies the side effects and best dose of modified immune cells (IL13Ralpha2 CAR T cells) after a chemotherapy conditioning regimen for the treatment of...

Sponsor: Anusha KalbasiEnrolling: 183 locations
RECRUITINGPhase 1NCT06451497

This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With...

This is a phase 1 dose escalation trial of ZM008, an anti-LLT1 antibody as a single agent followed by combination with Toripalimab in patients with advanced solid tumors who have...

Sponsor: Zumutor Biologics Inc.Enrolling: 1003 locations
RECRUITINGPhase 1NCT06789172

A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors

The purpose of this study is to investigate the study drug, OKN4395, administered alone and in combination with pembrolizumab. The overall objectives of this study are to...

Sponsor: EpkinEnrolling: 16610 locations
RECRUITINGPhase 1 / Phase 2NCT03556228

VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

This is a multicenter, open-label, Phase 1/2 study of orally administered VMD-928 monotherapy and in combination with pembrolizumab in adult subjects with advanced solid tumors or...

Sponsor: VM Oncology, LLCEnrolling: 24215 locations
RECRUITINGPhase 1NCT05983432

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-B01D1 in patients with Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and...

Sponsor: SystImmune Inc.Enrolling: 47020 locations
RECRUITINGPhase 2NCT06378177

A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC)

The purpose of this study is to assess the safety and efficacy of LVGN6051 (4-1BB agonistic antibody) combined with toripalimab (anti-PD-1 antibody) and paclitaxel (anti-tubulin...

Sponsor: Lyvgen Biopharma Holdings LimitedEnrolling: 6417 locations
RECRUITINGPhase 2NCT06693323

Single-Center Eval of Clinical & Radiological Benefit AHCC in Combo W/ SOC Tx for HPV+ Pts W/ HNSCC

This is a phase 2, single-arm, open-label clinical trial determining safety and tolerability of AHCC in subjects with HPV-positive patients with Head and Neck Squamous Cell...

Sponsor: University of California, IrvineEnrolling: 341 location
RECRUITINGPhase 2NCT05343325

The Efficacy and Safety of Neoadjuvant Low-dose Radiotherapy Combined With Chemoimmunotherapy in Locally Advanced HNSCC

This is an open-label, single-arm, phase II clinical trial to explore the efficacy and safety of neoadjuvant low-dose radiotherapy combined with chemoimmunotherapy in resectable...

Sponsor: Fifth Affiliated Hospital, Sun Yat-Sen UniversityEnrolling: 252 locations
RECRUITINGPhase 3NCT06496178

A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and...

This is a phase 3 open-label, randomized, controlled, multicenter study to compare petosemtamab vs investigator's choice monotherapy in HNSCC patients for the second- and...

Sponsor: Merus B.V.Enrolling: 50020 locations
RECRUITINGPhase 1NCT05901545

Evaluating 111In Panitumumab for Nodal Staging in Head and Neck Cancer

This phase I trial tests the safety and effectiveness of indium In 111 panitumumab (111In-panitumumab) for identifying the first lymph nodes to which cancer has spread from the...

Sponsor: Vanderbilt-Ingram Cancer CenterEnrolling: 301 location
RECRUITINGPhase 3NCT06248996

a Multicentre Phase III Study of Risk-based Treatment Intensification With Hyperfractionated Radiotherapy in Head and...

There is an unmet need to personalise treatment for patients with head and neck squamous cell carcinoma (HNSCC) and to improve treatment results for patients with advanced...

Sponsor: Lund University HospitalEnrolling: 30811 locations
RECRUITINGPhase 1NCT05107674

A Study of NX-1607 in Adults With Advanced Malignancies

This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced...

Sponsor: Nurix Therapeutics, Inc.Enrolling: 34517 locations
RECRUITINGPhase 1NCT06444815

A Study of VET3-TGI in Patients With Solid Tumors

VET3-TGI is an oncolytic immunotherapy designed to treat advanced cancers. VET3-TGI has not been given to human patients yet, and the current study is designed to find a safe and...

Sponsor: KaliVir ImmunotherapeuticsEnrolling: 607 locations
RECRUITINGNCT06575322

Effects of Neoadjuvant Therapy With Carboplatin, Paclitaxel Combined With Anti-PD-1 Drugs on Pain, Anxiety and...

The goal of this observational study is to learn about the Effects of neoadjuvant therapy with carboplatin, paclitaxel combined with anti-PD-1 drugs on pain, anxiety and...

Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityEnrolling: 3021 location
RECRUITINGPhase 2NCT06494995

AK104 and Low-dose Radiation in Recurrent/Metastatic HNSCC After Failure of First-line Systemic Therapy

Currently, there is a lack of high-quality clinical evidence for subsequent treatment options for recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) after...

Sponsor: Fudan UniversityEnrolling: 521 location